New York, 03, 2020: A 12-week study by Hoth Therapeutics suggests the potential of WEG232, a topical treatment for hair loss in reducing the side effects of Erlotinib. Erlotinib is a frequently used agent that combats several cancers but can result in serious side effects including hair loss. The research with 25 SD-rats, took place at George Washington University and indicated that topical application of WEG232 could be effective in suppressing erlotinib induced-facial rash/hair loss. Roth CEO, Robb Knie, commented, “This study showed compelling results with a 71% facial rash and hair loss reduction.”
This site uses Akismet to reduce spam. Learn how your comment data is processed.